Stock·NASDAQ·Healthcare
Intuitive Surgical Inc. (ISRG)
- Market cap
- $159.55B
- P/E
- 54.69
- Dividend yield
- None
- Street target
- $485.50median of 34 analysts
- 52-week range
- $328.57 $603.88
ISRG stock forecast today
Where ISRG stands today, and what CleaRank Financial AI makes of it.
ISRG at a glance
Intuitive Surgical Inc. (ISRG): Buy, 69/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($397.20 and $435.54).
- Earnings ISRG beat estimates in 8 of its last 8 quarters, yet fell the next day after 5 of those beats.
- Insiders Insiders sold $124.7M and made no open-market purchases over the last 18 months.
- Valuation P/E of 54.7 against 31.9 for the Healthcare sector: a premium to peers (+71%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Intuitive Surgical Inc. (ISRG) Buy, with a model score of 69/100.
Valuation holds it back most: the P/E of 54.69 is 71.4% above the sector median (a premium to peers) and the P/S of 13.80 is 305.9% above the sector median. The trend is up: ISRG trades 13.70% above its 50-day average of $397.20 and 3.69% above its 200-day average of $435.54. Over the past year the price fell 17.36%.
Only on CleaRank
Figures we compute ourselves from ISRG's own price, earnings and insider-filing history. Tap one to see it in context.
ISRG stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
2/4Price above its 50-day average ›
The price of $451.63 is 13.7% above the 50-day simple moving average of $397.20.Price above its 200-day average ›
The price is 3.7% above the 200-day simple moving average of $435.54.50-day average above the 200-day ›
The 50-day average ($397.20) is 8.8% below the 200-day average ($435.54), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 45% of its 52-week range, between $328.57 and $603.88.
ISRG share price
Pick a period: each tab shows how far ISRG has moved over it, to the last close.
Today's trading
Where ISRG sits inside today's range and its 52-week range.
ISRG fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 54.69 is 71.4% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 13.80 is 305.9% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $3.0B on revenue of $11.6B, a net margin of 25.5%.Beat estimates in most recent reports ›
ISRG beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for ISRG.
As of October 26, 2026, ISRG trades at $451.63, with a market value of $159.55B and a P/E ratio of 54.69.
What the numbers say
CleaRank Financial AI's reading of ISRG's valuation, growth and risks.
Against the 31.9 median P/E of Healthcare stocks, Intuitive Surgical Inc. (ISRG)'s P/E of 54.69 is 71.4% above that median, which counts as a premium to peers. Measured against sales, the P/S of 13.80 is 305.9% above the sector median of 3.4. The company has a market value of $159.6B and trailing earnings of $8.27 a share.
On profitability, the net margin stands at 25.54% and the operating margin at 33.29%. Return on equity is 17.93%, above the sector median of 7.3%. Debt-to-equity is 0.00.
ISRG reported EPS of $3.00 in its latest quarterly report on October 20, 2026, topping the $2.64 estimate and beating it by 13.64%. The share price nonetheless fell 2.26% in the first session after the report.
Across its last 8 reports, ISRG beat the estimate every time; even so, 5 of those 8 beats were followed by a lower share price the next session. Looking ahead, analysts expect EPS of $11.25 this fiscal year (growth of 26.0%) and $12.43 the year after (growth of 10.4%).
Intuitive Surgical Inc. (ISRG) has less room for error on valuation, since its P/E of 54.69 is 71.4% above the sector median, which is a premium to peers. Typical daily moves for the stock run about 1.61%, and its beta against the S&P 500 is 1.46. The price is 25.21% below the 52-week high of $603.88. Insiders sold $124.7M of stock over the last 18 months and made no open-market purchases. Those sales may have been planned or made to cover tax on vesting shares, which makes them a weaker signal than buying would be.
ISRG against the Healthcare sector
How ISRG compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: ISRG trades at a significant premium to sector peers (+71%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 14, 2025, ISRG has lost 20.2% against a gain of 39.2% for XLV.
Performance against XLV
ISRG and the Healthcare sector fund over the same days.
Revenue and earnings
How much ISRG sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); ISRG reported again on October 20, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 20.5% in FY2025 to $10.1B, from $8.4B a year earlier.
Profit margin: The net margin was 28.6% in FY2025, up from 28.0% the year before.
Profitable: ISRG earned $2.9B in FY2025.
Earnings reality check
Did ISRG beat what analysts expected, and how did the stock react?
Earnings record: ISRG beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 5 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 20, 2026after close | $2.64 | $3.00 | +13.64% | -2.26% | - |
| Jul 16, 2026after close | $2.50 | $2.80 | +12.00% | -14.15% | -17.48% |
| Apr 21, 2026after close | $2.11 | $2.50 | +18.48% | +7.16% | +3.40% |
| Jan 22, 2026after close | $2.27 | $2.53 | +11.45% | -0.35% | -3.47% |
| Oct 21, 2025after close | $1.99 | $2.40 | +20.60% | +13.89% | +17.86% |
| Jul 22, 2025after close | $1.92 | $2.19 | +14.06% | -1.77% | -2.77% |
| Apr 22, 2025after close | $1.73 | $1.81 | +4.62% | +1.92% | +7.55% |
| Jan 23, 2025after close | $1.79 | $2.21 | +23.46% | -4.04% | -4.68% |
As of October 26, 2026, ISRG has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 5 of those beats; its latest report, on October 20, 2026, came in 13.64% above the estimate and the stock moved -2.26% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
ISRG AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 70.3, in overbought territory.RSI above 50 ›
An RSI of 70.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of ISRG
The score, the reasoning behind it, and what could move the price next.
Intuitive Surgical Inc. (ISRG) is trending up. The price of $451.63 sits 13.70% above its 50-day average of $397.20 and 3.69% above its 200-day average of $435.54. Still, the 50-day average is 8.80% below the 200-day, so the recovery has yet to lift the shorter average past the longer one. The price stands at 45% of its 52-week range, which runs from $328.57 up to $603.88.
Momentum is strong in the short term. The 14-day RSI sits at 70.3, which is in the overbought zone, and the MACD line is positive. Against that, the longer record is mixed: the price is up 11.46% over the past month and 26.57% over the past three months, yet it is down 17.36% over the past year.
Rating reaffirmed ›
Leerink Partners kept its Outperform rating on October 21, 2026.
Source: Analyst action, Leerink Partners, October 21, 2026
Earnings beat, but the stock fell ›
The October 20, 2026 report beat the EPS estimate by 13.64%, and the share price fell 2.26% in the first session after it.
Source: Earnings report, October 20, 2026
- Keep an eye on the two closest levels: the 52-week high at $603.88 above the price, and the 200-day SMA at $435.54 below it.
- A 14-day RSI of 70.3 puts ISRG in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- ISRG beat estimates in 8 of the last 8 reports. After the October 20, 2026 report, though, the share price fell 2.26% in the first session.
ISRG is above its 50-day and 200-day moving averages ($397.20 and $435.54), and that is why the trend reads up. If the price slipped under the 200-day, that would be the first warning sign. The nearest support beneath the price is the 200-day SMA at $435.54.
The next level overhead for ISRG is the 52-week high at $603.88. The RSI sits in overbought territory, so a pause would not on its own break the trend. A slide back below the bullish zone would be the sign that momentum is fading.
Technical indicators
Momentum and trend for ISRG, from its daily closes.
As of October 26, 2026, with ISRG at $451.63, its 14-day RSI is 70.3 (overbought territory), its 50-day simple moving average is $397.20 and its 200-day is $435.54.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What ISRG moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, ISRG's 1-year correlation of daily returns is +0.52 with S&P 500 (SPY), +0.45 with Nasdaq 100 (QQQ), +0.13 with Bitcoin (BTC) and +0.03 with gold (XAU).
ISRG price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
26 of 34 analysts rate it a buy or strong buy, 6 a hold and 2 a sell.Median target above the price ›
The median 12-month target of $485.50 is 7.5% above the price.More buy ratings than three months ago ›
26 of 34 rate it a buy now, against 23 of 33 three months ago.
ISRG Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 21, 2026 | Leerink Partners | Maintains | Outperform |
| Oct 21, 2026 | JP Morgan | Maintains | Overweight |
| Oct 21, 2026 | Evercore ISI Group | Maintains | In-Line |
| Oct 21, 2026 | Wells Fargo | Maintains | Overweight |
| Oct 21, 2026 | TD Cowen | Reiterates | Buy |
| Oct 21, 2026 | Barclays | Maintains | Overweight |
As of October 26, 2026, 34 Wall Street analysts cover ISRG: 26 rate it a buy or strong buy, 6 a hold and 2 a sell or strong sell. Their 12-month price targets range from $324.00 to $685.00. The median ISRG price target is $485.50, 7.5% above the price of $451.63.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
ISRG trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ISRG trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ISRG's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ISRG tends to move, against the market and on its own.
ISRG price history and drawdowns
ISRG's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.61% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 48.2%, from November 2021 to September 2022, regained by January 2024.Most 1-year holds ended higher ›
74% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $61,286, against $42,015 in the S&P 500 (SPY).
ISRG Drawdowns & Recovery
As of October 26, 2026, ISRG's worst peak-to-trough fall over the last 10 years with dividends reinvested was -48.2% (November 2021 to September 2022); it regained that peak by January 2024, 16 months after the low, and 74% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ISRG in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ISRG beat the S&P 500 over this period: $61,286 against $42,015.
A $10,000 investment in ISRG in October 2016 would be worth about $61,286 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ISRG, and which have not.
Strongest month, November: an average of +5.67%, up in 8 of 10 years.
Weakest month, March: an average of -2.27%, up in 5 of 10 years.
This month, October: has averaged +4.89%, up in 7 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ISRG's strongest calendar month has been November (average +5.67%, up in 8 of 10 years) and its weakest March (average -2.27%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
ISRG stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ISRG, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in ISRG today could grow to about $14,762 by 2030 in the base case, with a 90th-percentile outcome near $34,561 and a 10th-percentile outcome around $6,305. Projections are statistical simulations, not guarantees.
ISRG Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $667 for ISRG by 2030 in the base case, from $452 today (1.5x over 4 years). The 10th-percentile path ends near $285. These are outcomes of a Monte Carlo simulation run on ISRG's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $325 | $498 | $762 | |
| 2028 | $301 | $549 | $1,001 | |
| 2029 | $290 | $605 | $1,264 | |
| 2030 | $285 | $667 | $1,561 |
Method: a lognormal simulation of ISRG's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
ISRG insider trading
What the people running the company have bought and sold.
ISRG insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought ISRG shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 26, 2026, ISRG insiders reported 56 open-market sales worth $124.7M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 9, 2026 | Gary Loeb
Officer
|
Grant | 2.6K | - |
| Oct 9, 2026 | Patricia L. Wadors
Officer
|
Grant | 2.1K | - |
| Sep 15, 2026 | Fredrik Widman
Officer
|
Sell | 1.1K | $407.8K |
| Sep 15, 2026 | Fredrik Widman
Officer
|
Option | 1.1K | $102.9K |
| Sep 11, 2026 | Mark Preston Brosius
Officer
|
Sell | 48 | $17.1K |
| Sep 9, 2026 | Mark Preston Brosius
Officer
|
Sell | 69 | $24.7K |
| Aug 21, 2026 | Mark Preston Brosius
Officer
|
Sell | 154 | $59.4K |
| Aug 19, 2026 | Mark Preston Brosius
Officer
|
Sell | 231 | $90.8K |
| Aug 11, 2026 | Gary S Guthart
Director
|
Sell | 10.0K | $4.0M |
| Aug 11, 2026 | Amy L Ladd
Director
|
Sell | 472 | $179.9K |
| Aug 10, 2026 | Gary Loeb
Officer
|
Sell | 400 | $151.6K |
| Jul 31, 2026 | Mark Preston Brosius
Officer
|
Sell | 56 | $19.5K |
| Jul 29, 2026 | Mark Preston Brosius
Officer
|
Sell | 84 | $30.0K |
| Jul 10, 2026 | David J Rosa
Chief Executive Officer
|
Grant | 1.9K | - |
| Jun 12, 2026 | Mark Preston Brosius
Officer
|
Sell | 48 | $19.8K |
| Jun 10, 2026 | Gary Loeb
Officer
|
Sell | 400 | $169.7K |
| Jun 10, 2026 | Mark Preston Brosius
Officer
|
Sell | 69 | $29.1K |
| Jun 10, 2026 | David J Rosa
Chief Executive Officer
|
Grant | 1.4K | - |
| Jun 1, 2026 | Iman Jeddi
Officer
|
Sell | 5.6K | $2.4M |
| Jun 1, 2026 | Iman Jeddi
Officer
|
Option | 5.6K | $433.1K |
| May 22, 2026 | Mark Preston Brosius
Officer
|
Sell | 36 | $15.9K |
| May 20, 2026 | Mark Preston Brosius
Officer
|
Sell | 54 | $23.5K |
| May 11, 2026 | Gary Loeb
Officer
|
Sell | 400 | $178.8K |
| Apr 30, 2026 | Craig H Barratt
Director
|
Grant | 750 | - |
| Apr 30, 2026 | Joseph C Beery
Director
|
Grant | 531 | - |
| Apr 30, 2026 | Lewis Chew
Director
|
Grant | 531 | - |
| Apr 30, 2026 | Amal M Johnson
Director
|
Grant | 531 | - |
| Apr 30, 2026 | Sreelakshmi Kolli
Director
|
Grant | 531 | - |
| Apr 30, 2026 | Amy L Ladd
Director
|
Grant | 531 | - |
| Apr 30, 2026 | Keith R Leonard Jr
Director
|
Grant | 531 | - |
| Apr 30, 2026 | Jami Dover K Nachtsheim
Director
|
Grant | 531 | - |
| Apr 30, 2026 | Monica P Reed
Director
|
Grant | 531 | - |
| Apr 29, 2026 | Amy L Ladd
Director
|
Sell | 619 | $291.9K |
| Mar 10, 2026 | Mcadams Myriam J Curet
Officer
|
Sell | 105 | $51.9K |
| Mar 10, 2026 | Mcadams Myriam J Curet
Officer
|
Option | 105 | $24.1K |
| Mar 9, 2026 | Mark Preston Brosius
Officer
|
Sell | 1.3K | $630.5K |
| Mar 5, 2026 | Mark Preston Brosius
Officer
|
Sell | 3.7K | $1.8M |
| Mar 3, 2026 | Myriam J Curet
Officer
|
Sell | 4.9K | $2.4M |
| Mar 3, 2026 | Fredrik Widman
Officer
|
Sell | 367 | $181.9K |
| Mar 2, 2026 | Myriam J Curet
Officer
|
Option | 125 | $26.1K |
| Feb 27, 2026 | Myriam J Curet
Officer
|
Sell | 2.3K | $1.2M |
| Feb 27, 2026 | Patricia L. Wadors
Officer
|
Sell | 220 | $109.9K |
| Feb 27, 2026 | Mark Preston Brosius
Officer
|
Grant | 9.3K | - |
| Feb 27, 2026 | Henry L Charlton
Officer
|
Grant | 11.5K | - |
| Feb 27, 2026 | Myriam J Curet
Officer
|
Grant | 9.4K | - |
| Feb 27, 2026 | Gary S Guthart
Director
|
Grant | 28.8K | - |
| Feb 27, 2026 | Gary Loeb
Officer
|
Grant | 3.1K | - |
| Feb 27, 2026 | David J Rosa
Chief Executive Officer
|
Grant | 24.9K | - |
| Feb 27, 2026 | Jamie E. Samath
Officer
|
Grant | 11.5K | - |
| Feb 27, 2026 | Fredrik Widman
Officer
|
Grant | 468 | - |
| Feb 26, 2026 | Mark Preston Brosius
Officer
|
Grant | 2.6K | - |
| Feb 26, 2026 | Henry L Charlton
Officer
|
Grant | 2.7K | - |
| Feb 26, 2026 | Myriam J Curet
Officer
|
Grant | 4.7K | - |
| Feb 26, 2026 | Gary S Guthart
Director
|
Grant | 8.4K | - |
| Feb 26, 2026 | Gary Loeb
Officer
|
Grant | 2.4K | - |
| Feb 26, 2026 | David J Rosa
Chief Executive Officer
|
Grant | 6.1K | - |
| Feb 26, 2026 | Jamie E. Samath
Officer
|
Grant | 3.4K | - |
| Feb 26, 2026 | Patricia L. Wadors
Officer
|
Grant | 458 | - |
| Feb 26, 2026 | Fredrik Widman
Officer
|
Grant | 989 | - |
| Feb 11, 2026 | Myriam J Curet
Officer
|
Sell | 526 | $260.3K |
| Feb 11, 2026 | Fredrik Widman
Officer
|
Sell | 133 | $65.8K |
| Feb 10, 2026 | Mark Preston Brosius
Officer
|
Grant | 838 | - |
| Feb 10, 2026 | Henry L Charlton
Officer
|
Grant | 1.1K | - |
| Feb 10, 2026 | Myriam J Curet
Officer
|
Option | 943 | $24.1K |
| Feb 10, 2026 | Gary S Guthart
Director
|
Grant | 2.6K | - |
| Feb 10, 2026 | Gary Loeb
Officer
|
Grant | 315 | - |
| Feb 10, 2026 | David J Rosa
Chief Executive Officer
|
Grant | 1.4K | - |
| Feb 10, 2026 | Jamie E. Samath
Officer
|
Grant | 1.1K | - |
| Feb 10, 2026 | Fredrik Widman
Officer
|
Grant | 567 | - |
| Jan 29, 2026 | Myriam J Curet
Officer
|
Sell | 126 | $65.5K |
| Jan 29, 2026 | Myriam J Curet
Officer
|
Option | 126 | $26.3K |
| Jan 27, 2026 | Gary S Guthart
Director
|
Sell | 27.3K | $14.5M |
| Jan 27, 2026 | Myriam J Curet
Officer
|
Sell | 230 | $122.5K |
| Jan 27, 2026 | Myriam J Curet
Officer
|
Option | 230 | $50.2K |
| Jan 27, 2026 | Gary S Guthart
Director
|
Option | 25.5K | $4.4M |
| Dec 15, 2025 | Mark Preston Brosius
Officer
|
Sell | 5.0K | $2.7M |
| Dec 12, 2025 | Mark Preston Brosius
Officer
|
Sell | 4.8K | $2.6M |
| Dec 12, 2025 | Mark Preston Brosius
Officer
|
Option | 4.5K | $358.4K |
| Dec 10, 2025 | Myriam J Curet
Officer
|
Sell | 104 | $58.2K |
| Dec 10, 2025 | Myriam J Curet
Officer
|
Option | 104 | $23.9K |
| Dec 1, 2025 | Gary S Guthart
Officer and Director
|
Sell | 22.8K | $13.0M |
| Dec 1, 2025 | Myriam J Curet
Officer
|
Sell | 125 | $71.1K |
| Dec 1, 2025 | Myriam J Curet
Officer
|
Option | 125 | $26.1K |
| Dec 1, 2025 | Gary S Guthart
Officer and Director
|
Option | 25.5K | $3.6M |
| Nov 12, 2025 | Henry L Charlton
Officer
|
Sell | 13.7K | $8.0M |
| Nov 12, 2025 | Craig H Barratt
Director
|
Sell | 750 | $435.0K |
| Nov 12, 2025 | Craig H Barratt
Director
|
Option | 750 | $53.5K |
| Nov 12, 2025 | Henry L Charlton
Officer
|
Option | 9.0K | $2.1M |
| Nov 12, 2025 | Keith R Leonard Jr
Director
|
Grant | 1.6K | - |
| Nov 10, 2025 | Brian Edward Miller
Officer
|
Sell | 3.5K | $2.0M |
| Nov 10, 2025 | Myriam J Curet
Officer
|
Sell | 105 | $58.8K |
| Nov 10, 2025 | Myriam J Curet
Officer
|
Option | 105 | $24.1K |
| Nov 10, 2025 | Brian Edward Miller
Officer
|
Option | 3.5K | $757.7K |
| Nov 5, 2025 | Fredrik Widman
Officer
|
Sell | 2.1K | $1.1M |
| Nov 5, 2025 | Fredrik Widman
Officer
|
Option | 2.1K | $156.4K |
| Nov 3, 2025 | David J Rosa
Chief Executive Officer
|
Grant | 5.5K | - |
| Oct 29, 2025 | Myriam J Curet
Officer
|
Sell | 7.7K | $4.2M |
| Oct 29, 2025 | Myriam J Curet
Officer
|
Option | 7.7K | $1.8M |
| Oct 24, 2025 | Gary S Guthart
Officer and Director
|
Sell | 31.6K | $17.3M |
| Oct 24, 2025 | David J Rosa
Chief Executive Officer
|
Sell | 24.5K | $13.4M |
| Oct 24, 2025 | Craig H Barratt
Director
|
Sell | 2.2K | $1.2M |
| Oct 24, 2025 | Craig H Barratt
Director
|
Option | 2.2K | $156.4K |
| Oct 24, 2025 | Gary S Guthart
Officer and Director
|
Option | 36.0K | $3.9M |
| Oct 24, 2025 | David J Rosa
Chief Executive Officer
|
Option | 27.0K | $2.2M |
| Oct 10, 2025 | Gary Loeb
Officer
|
Grant | 2.6K | - |
| Sep 4, 2025 | Amy L Ladd
Director
|
Sell | 671 | $305.6K |
| Aug 29, 2025 | Gary S Guthart
Officer and Director
|
Sell | 29.4K | $13.9M |
| Aug 29, 2025 | Gary S Guthart
Officer and Director
|
Option | 36.0K | $2.9M |
| Jul 28, 2025 | Gary S Guthart
Officer and Director
|
Sell | 10.7K | $5.3M |
| Jul 28, 2025 | Gary S Guthart
Officer and Director
|
Option | 7.9K | $469.3K |
| Jul 28, 2025 | Gary S Guthart
Officer and Director
|
Grant | 10.5K | - |
| Jul 25, 2025 | Myriam J Curet
Officer
|
Sell | 4.5K | $2.2M |
| Jul 25, 2025 | Myriam J Curet
Officer
|
Option | 4.5K | $1.1M |
| Jun 10, 2025 | David J Rosa
President
|
Grant | 1.4K | - |
| Jun 6, 2025 | Mark Preston Brosius
Officer
|
Sell | 431 | $242.2K |
| Jun 4, 2025 | Mark Preston Brosius
Officer
|
Sell | 645 | $355.1K |
| Jun 4, 2025 | David J Rosa
President
|
Grant | 851 | - |
| May 16, 2025 | Mark Preston Brosius
Officer
|
Sell | 42 | $23.6K |
| May 14, 2025 | Mark Preston Brosius
Officer
|
Sell | 66 | $36.9K |
| May 2, 2025 | Jamie E. Samath
Chief Financial Officer
|
Sell | 915 | $483.1K |
Source: TwelveData, from SEC Form 4 filings
ISRG stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.